Crossmark

Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)

Crossref DOI link: https://doi.org/10.1186/s42358-020-00125-9

Published Online: 2020-05-27

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Balbi, Gustavo Guimarães Moreira http://orcid.org/0000-0003-0235-8834
Pacheco, Marcelo de Souza

Monticielo, Odirlei Andre

Funke, Andreas

Danowski, Adriana

Santiago, Mittermayer Barreto

Staub, Henrique Luiz

Rêgo, Jozelia

de Andrade, Danieli Castro Oliveira
License Information

Text and Data Mining valid from 2020-05-27

Version of Record valid from 2020-05-27
More Information

Article History

Received: 28 October 2019

Accepted: 8 April 2020

First Online: 27 May 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below